Payment overview · 2025
General Payments
$2,323.03
133 reported records · 22 companies
Healthcare provider profile · identity verified
Keith Alan Georger, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARNOLD, MO · NPI 1649581745
Verified facts
What the public records show
CMS Open Payments records show Keith Alan Georger, M.D. received $2,323.03 in general payments during 2025 across 133 reported records.
ABBVIE INC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $417.91 | 18.0% | 27 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $276.62 | 11.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $256.68 | 11.1% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $252.21 | 10.9% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.42 | 6.3% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.02 | 6.2% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $121.93 | 5.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $101.17 | 4.4% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $84.57 | 3.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.51 | 3.0% | 4 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $67.07 | 2.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.76 | 2.4% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.07 | 2.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.66 | 2.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.43 | 2.0% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $46.29 | 2.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.23 | 1.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.72 | 1.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.02 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.96 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.86 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.92 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,284.49 | 132 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $192.89 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $166.37 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.43 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $135.10 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $123.80 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $116.44 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $116.02 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $113.32 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $106.73 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.74 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $103.45 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $102.11 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $101.17 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $91.20 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $91.20 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $82.79 | 5 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $67.07 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.37 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $59.32 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.22 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.76 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.61 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.61 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.66 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.43 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $46.29 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.91 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.91 | 4 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $35.45 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 30 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 129 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 168 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
168 | 41 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 943 | 268 |
| Amlodipine Besylate | Amlodipine Besylate | 540 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 507 | 136 |
| Alprazolam | Alprazolam | 446 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 441 | 111 |
| Losartan Potassium | Losartan Potassium | 406 | 122 |
| Lisinopril | Lisinopril | 402 | 109 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 357 | 104 |
| Tramadol Hcl | Tramadol Hcl | 341 | 71 |
| Gabapentin | Gabapentin | 320 | 84 |
| Meloxicam | Meloxicam | 290 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 273 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 64 |
| Omeprazole | Omeprazole | 244 | 67 |
| Metformin Hcl | Metformin Hcl | 242 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 66 |
| Trazodone Hcl | Trazodone Hcl | 234 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 230 | 57 |
| Montelukast Sodium | Montelukast Sodium | 225 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 47 |
| Sertraline Hcl | Sertraline Hcl | 198 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 55 |
| Carvedilol | Carvedilol | 192 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 178 | 47 |
| Simvastatin | Simvastatin | 169 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 168 | 41 |
| Furosemide | Furosemide | 154 | 50 |
| Lorazepam | Lorazepam | 137 | 22 |
| Alendronate Sodium | Alendronate Sodium | 135 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 36 |
| Metformin Hcl Er | Metformin Hcl | 135 | 39 |
| Eliquis | Apixaban | 129 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 27 |
| Glipizide | Glipizide | 108 | 31 |
| Ozempic | Semaglutide | 102 | 29 |
| Pregabalin | Pregabalin | 99 | 17 |
| Buspirone Hcl | Buspirone Hcl | 96 | 30 |
| Mounjaro | Tirzepatide | 92 | 16 |
| Allopurinol | Allopurinol | 91 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 21 |
| Spironolactone | Spironolactone | 82 | 26 |
| Methylprednisolone | Methylprednisolone | 80 | 71 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 22 |
| Jardiance | Empagliflozin | 76 | 19 |
| Diazepam | Diazepam | 74 | 16 |
| Farxiga | Dapagliflozin Propanediol | 74 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 23 |
| Potassium Chloride | Potassium Chloride | 64 | 21 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 19 |
| Ondansetron Odt | Ondansetron | 62 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 62 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 12 |
| Mirtazapine | Mirtazapine | 61 | 21 |
| Temazepam | Temazepam | 61 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 11 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Finasteride | Finasteride | 57 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 14 |
| Celecoxib | Celecoxib | 52 | 16 |
| Fenofibrate | Fenofibrate | 52 | 15 |
| Naproxen | Naproxen | 52 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 14 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 15 |
| Famotidine | Famotidine | 50 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 12 |
| Cephalexin | Cephalexin | 47 | 42 |
| Eszopiclone | Eszopiclone | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Torsemide | Torsemide | 43 | 14 |
| Atenolol | Atenolol | 42 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Prednisone | Prednisone | 39 | 12 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | 15 |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Topiramate | Topiramate | 33 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | 11 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Belsomra | Suvorexant | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Nystatin | Nystatin | 21 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 13 |
| Nitroglycerin | Nitroglycerin | 19 | 16 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,323.03 · 133 records | ABBVIE INC. | AIRSUPRA, AREXVY, AZMIRO, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dyanavel XR, EDARBI, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error